MedTrace Logo

Role of the Catechol-O-methyltransferase (COMT) in the Physiological Regulation of Vigilance

NCT02080715 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2014-09-12

No results posted yet for this study

Summary

In this study, pharmacologic effects of COMT inhibition during sleep deprivation in healthy subjects in dependence of their Val158Met genotype of COMT are studied. Potential effects are identified by measurement of vigilance and cognitive performance as well as EEG measurements during wake and sleep.

* Trial with medicinal product

Conditions

  • Healthy

Interventions

DRUG

Tolcapone

2 x 100mg Tolcapone compared to placebo (randomized, double-blind, cross-over)

DRUG

Placebo

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Hans-Peter Landolt, Professor · University of Zurich, Institute of Pharmacology and Toxicology

  • Christian Baumann, MD · University Hospital Zurich, Department of Neurology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
30 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02080715 on ClinicalTrials.gov